TetraLogic Pharmaceuticals Corporation

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

Gilead Sciences Inc. won approval from the US FDA on Nov. 10 for its second generation hepatitis B drug Vemlidy ; the compound will be priced in line with its predecessor drug, Gilead's own Viread

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Oct. 31-Nov. 8. Deal